Treatment with an aromatase inhibitor improves outcomes at 10 years compared to treatment with a SERM in HR+, HER2+ early breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback